Insulin Potentiation Therapy (IPT)
Insulin potentiation therapy (IPT) has been around for a long time. IPT was discovered by Donato Perez Garcia, M.D., and developed by him in Mexico City during the 1930s and 1940s. Following its discovery, its chief practitioners were three generations of the Garcia doctors, who called it cellular therapy or Donatian therapy. In the 1970s or 1980s it was renamed Insulin Potentiation Therapy.
The key to IPT as a treatment lies in the off-label use of insulin, a hormone made by the body. Insulin is responsible for the delivery of glucose from the bloodstream, across cell membranes, and into the cells. Certain diseases such as Lyme disease and cancer have up to 20 times more insulin receptors on their surface than normal cells because they require glucose for their energy production. When insulin is released into the bloodstream by the pancreas in response to a meal, the insulin attaches to these receptors on the surface of the cell and, like a key fitting into a lock, opens channels in the cell wall to allow nutrients to go into the cell.
Because Lyme and cancer cells have more of these insulin receptors, they outcompete the body’s normal cells for resources – namely, glucose. IPT uses that extreme need for sugar to its advantage, by opening the cellular membranes for significantly better absorption and permeability. This permeability is essential to move substances, including drugs, from the bloodstream into the cell so that they can exert their effects.
In the context of alternative Lyme disease and cancer treatment, Insulin Potentiation Therapy uses a combination of orthodox drugs such as insulin and chemotherapy, and takes advantage of both Lyme and cancer’s highly active insulin receptors, to provide treatment.